Taiho Pharmaceutical Company Ltd.
45 articles about Taiho Pharmaceutical Company Ltd.
The regulator Wednesday approved expanding Lonsurf’s label for previously treated metastatic colorectal cancer, authorizing a combination regimen with Roche’s bevacizumab.
The FDA had a fairly quiet week, approving drugs, providing clearance, greenlighting clinical trials, and other regulatory activities for Alnylam, Eli Lilly, Cytokinetics, and more.
FDA Approves Taiho's LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration has approved LYTGOBI® tablets for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements.
Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer
Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of overall survival (OS) compared to trifluridine/tipiracil alone in a Phase III clinical trial of participants with refractory metastatic colorectal cancer (mCRC) following two chemotherapy regimens.
Cullinan and Taiho announced that Taiho was acquiring Cullinan Pearl and will co-develop and co-commercialize their non-small cell lung cancer drug.
Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
Cullinan Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced an agreement through which Taiho will acquire Cullinan Pearl Corp. and co-develop and co-commercialize Cullinan Oncology’s lead program, CLN-081/TAS6417, an orally available, differentiated, irreversible EGFR inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations while sparing cells expressing wild-type EGFR.
Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan
Taiho Pharmaceutical Co., Ltd. and Helsinn Group, announced that Taiho has been granted approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market the NK1 receptor antagonist antiemetic drug “Arokaris® I.V. Infusion 235mg” for gastrointestinal symptoms associated with cancer chemotherapy.
Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia
Arcus Biosciences, Inc. and Taiho Pharmaceutical Co., Ltd. announced that Taiho exercised its option for anti-TIGIT antibodies domvanalimab and AB308 from Arcus Biosciences, in Japan and certain other territories in Asia.
“I hope to thread the needle between pricing responsibly and achieving profitability," Jarrett said.
Taiho and Lung Therapeutics Enter Into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions
Taiho Pharmaceutical Co., Ltd, and Lung Therapeutics, Inc. announced an exclusive license agreement of LTI-01, a recombinant human single-chain urokinase plasminogen activator, currently under development by Lung Tx for loculated pleural effusions, for the territory of Japan.
As Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd., continues to add early- and late-stage assets to its expanding oncology portfolio, the company announced the hiring of Stephen Yoder, MD, MBA as Vice President, Business Development, effective June 15, 2020.
VITRAC Therapeutics Initiated Global Clinical Development of VIC-1911, licensed from Taiho Pharmaceutical
VITRAC Therapeutics, LLC (VITRAC) initiated the global clinical development of VIC-1911, an oncology candidate formally known as TAS-119, which was licensed from Taiho Pharmaceutical Co., Ltd. (Taiho), a Japan-based oncology company. Two Phase-1 clinical studies have been conducted in the US and Europe by Taiho. VITRAC obtained an exclusive and global development and commercialization rights for TAS-119, and its IND has been succ
Arcus Biosciences and Taiho Pharmaceutical Co., Ltd. Jointly Announce Taiho’s Exercise of Its Option for an Exclusive License to Zimberelimab (AB122) for Its Territories in Japan and Other Asian Countries
Feb. 26, 2020 13:00 UTC Taiho’s in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus’s and Taiho’s oncology portfolios Zimberelimab exhibits clinical activity and a safety profile consistent with those of currently approved anti-PD-1 therapies Broad development program delivering randomized data in 2020 for zimberelimab in multiple novel combinations, including with AB154, Arcus’s a
Merck announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., and Astex Pharmaceuticals, a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd., focused on the development of small molecule inhibitors against several drug targets, including the KRAS oncogene, which are currently being investigated for the treatment of cancer.
The three-way deal is focused on the development of small molecule inhibitors against several drug targets, including the KRAS oncogene, which are currently being investigated for the treatment of cancer.
Taiho Pharmaceutical Co., Ltd. announced on August 29 that the company has entered into an agreement to invest up to US$30 million in Remiges Biopharma Fund II, LP a biopharma venture capital fund formed by Remiges Ventures, Inc.
Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor
FIH Study in EGFR Exon 20 Insertions Will Commence in 2019
Taiho Ventures Expands Investment Pool to US$300 Million to Continue Quality Investments and Accelerate Open Innovation
Taiho Ventures, LLC, a strategic corporate venture capital arm of Taiho Pharmaceutical, Co., Ltd., announced on October 16 that Taiho Ventures increased its investment pool by US$250 million from the initial US$50 million to US$300 million.
Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.
Taiho Oncology Presents Real-World Adherence Data for LONSURF® (trifluridine and tipiracil) in Metastatic Colorectal Cancer at ASCO Quality of Care Symposium
Taiho Oncology today announced real-world adherence data for patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF® (trifluridine and tipiracil) or Stivarga® (regorafenib).*